Another step towards marijuana research
I covered the ridiculous barriers to researching marijuana over at Healthcare Triage: But now the feds have taken another step towards making this better: The Obama administration is planning to remove a major roadblock to marijuana research, officials said Wednesday, potentially spurring broad scie
Why opioid substitution therapy is not just replacing one addiction for another
The following is the text of my email to Peter Friedmann, Brown University Professor of Medicine and Professor of Health Services, Policy & Practice and an expert on substance use and addiction medicine: In response to my NYT piece on treatment for opioid dependence, I received email with a question
Here’s another chart from the JAMA study “The Anatomy of Health Care in the United States“: From it, we can compute average health spending by age, in 2004. I’ve shown that below alongside an estimate of what that spending is today, assuming 2.5% growth per year since 2004, which seems at least roug
On The Record (with daily recap)
Kaiser: Drew Altman looks at what’s in store during 2012 Today in TIE: Don wonders who owns the MMSE and points out some good resources that can help you think about causation, while Aaron has two posts on paying for things that work: one focused on the macro level, and another on the doctor/patient
On The Record (with daily recap)
GAO: Health Oppty Accounts Demonstration in Medicaid BPC: Domenici-Rivlin Proect Medicare Act Brookings: Controlling Medicare Costs: Is Premium Support the Answer?(video archive soon) Today in TIE: Reflex, Fifth installment of Austin’s series on premium support in Medicare, and he shows that Med Adv
On The Record (with daily recap)
Today in TIE: Reflex, Austin takes another look at Romney’s reform ideas, and reviews the inconsistent way we worry about exchanges depending upon the age of the patients involved, Don wants to get the language straight on palliative care, and discusses the first lawsuit for not following a POLST fo
Kevin Drum has a piece up discussing Megan McArdle citing Derick Rowe: Via Megan McArdle, Derek Lowe blogs today about an entire field of pharmaceutical research revolving around PPAR ligands that pretty much went nowhere and cost drug companies a bundle: Allow me to rant for a bit, because I saw ye
